Glytec Receives Five Additional Patent Allowances for its Diabetes Therapy Management Software

My Subscriptions

Payment Confirmation

Transaction Failed

Your transaction failed, please try again or contact site support.

Glytec,  software solution for personalized diabetes therapy management, announces five new patent allowances for its eGlycemic Management System® (eGMS®), increasing the company’s portfolio to a total of 11 allowed or issued patents, with more than 50 pending.

Three of the new allowances were issued by the United States Patent and Trademark Office and two by the Israel Patent Office. The patents apply to proprietary systems and methods for intravenous and subcutaneous insulin therapies. They also address eGMS® integration with connected device systems — such as those which host and/or store blood glucose data — as well as enterprise health information systems, including electronic medical record systems (EMR); laboratory information systems (LIS); and admission, discharge and transfer systems (ADT).

“Technology innovation is one of Glytec’s core competencies, and it’s a significant investment for the company,” says Glytec’s Senior Vice President Research and Development, Robby Booth. “Our intellectual property protections, both here in the U.S. and abroad, speak to the unique and highly differentiated characteristics of our eGlycemic Management System®. Though, the improved clinical outcomes our clients achieve, and the associated cost savings, are the true testament of its worth.”

Glytec’s President and CEO, Bob Leonard adds: “A recent case study published by one of our clients — a large regional academic medical center — shows annualized savings in excess of $9.7 million using eGMS® to achieve best practice and reduce incidence of hypoglycemia for hospitalized patients. In other studies, we’ve demonstrated how using eGMS® leads to a decrease in readmissions of 35-68% and a sustained drop in A1C levels of 2.6 percentage points for chronic care populations, both of which result in improved quality of care and great economic benefit, especially in light of alternative reimbursement models. eGMS® is an enabling solution of value to health systems, payers and patients alike.”

Statistics from myriad organizations, including American Diabetes Association, International Diabetes Federation, and World Health Organization, point to the fact that diabetes is a global epidemic. “The difficulties associated with diabetes therapy management, especially insulin dosing and titration, are universal,” says Leonard. “Our intensive pursuit of both domestic and international patents formidably positions Glytec for broad geographic growth.”

Past News



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.